Glycemic behavior in patients with chronic kidney disease on hemodialysis using intermittent capillary glucose monitoring
PDF (Español (España))
HTML (Español (España))


Diabetes Mellitus
Chronic Kidney Disease
Hospital Hemodialysis Units
Blood Glucose

How to Cite

Pinzón Tovar , A. ., Álvarez Perdomo , L. C. ., Leiva, L. M. ., & Arrieta Mendoza, M. E. (2023). Glycemic behavior in patients with chronic kidney disease on hemodialysis using intermittent capillary glucose monitoring. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 10(3).


Context: Use of intermittent glucose monitoring in patients undergoing hemodialysis.
Objective: To describe the behavior of glucose through intermittent monitoring in patients with chronic kidney disease undergoing hemodialysis.
Methodology: An observational prospective study. Patients with chronic kidney disease of different causes undergoing hemodialysis were included. The glucometer readings results were analyzed before and during the hemodialysis session in 85 hospitalized patients; the glucometer readings values on the day of hemodialysis were studied in 47 outpatient patients.
Results: For this study, 132 patients were included, with a median age of 61 years, 54.5% female, most of them from Neiva, Huila. 93.9% had a history of hypertension, 63.6% had anemia, and 53.8% had diabetes mellitus, with an average time of renal replacement therapy of 3.05 years. The average glucometer reading at the start of hemodialysis was 18.9 mg/dl higher, compared to the post-dialysis value among patients with diabetes and only 14.0 mg/ dl in patients without diabetes. Regardless of the history of diabetes mellitus, the behavior of the glucometer readings was similar, with higher values at the start of therapy, followed by a subsequent decrease with few records of hypoglycemia.
Conclusions: In patients with chronic kidney disease on hemodialysis, intermittent capillary glucose monitoring shows an intradialytic decrease with subsequent elevation at the end of renal replacement therapy.
PDF (Español (España))
HTML (Español (España))


Carney EF. The impact of chronic kidney disease on global health. Nat Rev Nephrol. 2020 may.;16:251.

¿Qué es? ERC [Internet]. Cuenta de Alto Costo (CAC). 2022. [Citado 28 de octubre de 2022]. Disponible en:

Magnitud, tendencia y acceso a los servicios de salud en las personas con enfermedades de alto costo [Internet]. Cuenta de Alto Costo. [citado 28 de octubre de 2022]. Disponible en:

Acuña L, Sánchez P, Soler LA, Alvis LF. Enfermedad renal en Colombia : prioridad para la gestión de riesgo. Rev Panam Salud Pública. 2016 jul.;40:16-22. ISSN 1680-5348.

Higuita-Gutiérrez LF, Velasco-Castaño JJ, Jiménez Quiceno JN. Health-Related Quality of Life in Patients with Chronic Kidney Disease in Hemodialysis in Medellín (Colombia). Patient Prefer Adherence. 2019;13:2061-70.

Xu H, Carrero JJ. Insulin resistance in chronic kidney disease. Nephrology. 2017 dic.;22(S4),(spe iss. 1):31-34.

Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial. febrero de 2000 jan.;13(1):4-8.

Hahr AJ, Molitch ME. Management of Diabetes Mellitus in Patients With CKD: Core Curriculum 2022. Am J Kidney Dis. 2022 may.;79(5):728-736.

Blaine E, Tumlinson R, Colvin M, Haynes T, Whitley HP. Systematic literature review of insulin dose adjustments when initiating hemodialysis or peritoneal dialysis. Pharmacother. 2022 feb.;42(2):177-187.

Gai M, Merlo I, Dellepiane S, Cantaluppi V, Leonardi G, Fop F, et. al. Glycemic pattern in diabetic patients on hemodialysis: continuous glucose monitoring (CGM) analysis. Blood Purif. 2014 nov. 1;38(1):68-73.

Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012 nov. 1;82(9):952-960.

American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021 jan. 1;44(Supp.1):S15-S33.

Sobngwi E, Ashuntantang G, Ndounia E, Dehayem M, Azabji-Kenfack M, Kaze F, et. al. Continuous interstitial glucose monitoring in non-diabetic subjects with end-stage renal disease undergoing maintenance haemodialysis. Diabetes Res Clin Pract. 2010 oct.;90(1):22-25.

Jung HS, Kim HI, Kim MJ, Yoon JW, Ahn HY, Cho YM, et. al. Analysis of hemodialysis-associated hypoglycemia in patients with type 2 diabetes using a continuous glucose monitoring system. Diabetes Technol Ther. 2010 oct. 5;12(10):801-807.

Jaramillo Nieto A, Medina Orjuela A, Rosselli San Martin C, Rojas García W, Centeno García CD, Montoya Quesada LM. Monitoreo continuo de glucosa de seis días en pacientes diabéticos tipo 2 bajo hemodiálisis en tratamiento con insulinas en el Hospital de San José. (Bogotá). Rev Colomb Endocrinol Diabetes Metab. 2018 nov. 11;5(4):13-20.

Abe M, Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015 may.;11(5):302-313.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.